Revitalist Brings Together Impressive Team to Improve Mental Health
Ryan Allway
November 8th, 2021
Psychedelics, Top Story
Mental health disorders account for several of the top causes of disability in the U.S. and worldwide. In fact, 26% of Americans ages 18 and older—or about one in four adults—have a diagnosable mental disorder in a given year. In addition, nearly 10% of American adults will also suffer from a depressive illness, such as major depression, each year.
Let’s look at how Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) aims to tackle these problems with an impressive team and growing network of infusion clinics.
Taking a Unique Approach
Revitalist aims to address mental health disorders through a nationwide network of psychedelic-assisted psychotherapy clinics. As of September, the company has opened five clinics and signed letters of intent to expand its network to include ten additional facilities. These clinics provide short-term treatment via intensive outpatient programs.
According to Kentley Insights, the outpatient mental health industry generated over $25 billion in 2020 revenue and could grow at a 6.1% annual pace to reach $34 billion by 2025. As a first-mover in the space, Revitalist aims to build market share by providing some of the most cutting-edge treatments, such as ketamine IV infusions.
Click here to receive an investor presentation and corporate updates
The company’s clinics generate an average of $6,000 in revenue per patient, with three-quarters of that cost reimbursed by health insurance. These clinics offer IV ketamine infusions, ketamine-assisted psychotherapy, vitamin infusions, Spravato infusions, medical infusions, and transcranial magnetic stimulation (TMS) procedures.
Experienced Leadership
The success of any business depends on its leadership team. Fortunately, Revitalist has an impressive leadership team that’s well-qualified to grow the business over time. In addition to unparalleled medical expertise, the group includes veteran financiers and project managers that have a track record of growing $100M+ businesses.
Revitalist CEO Kathryn Walker, CRNA, SPMHNP
Chief Executive Officer Kathryn Walker, CRNA, SPMHNP, founded Revitalist in 2018. Since then, she has participated in thousands of infusions, leading an integrative team model of medical and mental health professionals. In particular, she has worked with clients considered treatment-resistant with chronic mood and pain symptoms.
Chief Medical Officer Dr. William Walker, MD, is a practicing physician with over 30 years of critical care and cardiothoracic experience. After serving as a Naval Commander in the military, Dr. Walker developed a profound appreciation for veteran mental health and remains committed to addressing mental health issues without contributing to the opioid crisis.
Click here to receive an investor presentation and corporate updates
VP of Operations Grant Whitfield has over 20 years of experience at private and public companies. Most recently, he helped grow a private $36M business to projected 2021 revenue of $219M as Director of Project Management. In the role, Mr. Whitfield was personally responsible for overseeing over $50M worth of accounts.
Chief Financial Officer Paul Ciullo is a 12-year veteran in senior corporate finance and accounting, holding numerous positions across Fortune 500 companies, including General Electric and Xerox. And VP of Finance Natasha Collins, CPA, CA, has managed ten public listings and participated in M&A and private placements worth over $180M.
Strong Supporting Team
The most successful companies also have strong advisory boards to help them navigate complex markets. To that end, Revitalisthas assembled a robust Advisory Board and Regulatory Board featuring medical experts across neuroscience, pain management, and other areas relevant to mental health treatments and therapeutics.
For example, the company’s Advisory Board includes Dr. Douglas Stofko, a board-certified neurosurgeon who provides specialized care for various brain and blood vessel conditions, including stroke, aneurysms, and tumors. The board also includes board-certified psychiatrist Dr. Ethan Bean and pain management specialist Dr. Jagdeep Gupta.
The company’s Regulatory Board includes Dr. Nick Kalynych, DNP, MSHS, CRNA, ARMP, a top nurse practicing since 1993, and five other specialists in anesthesiology, psychiatry, neurology, and other relevant fields where the company looks to have an impact. The group is uniquely positioned to help the business navigate complex regulatory frameworks.
Looking Ahead
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) aims to revolutionize the mental healthcare market through a nationwide network of clinics providing intensive outpatient programs, including psychedelic-assisted psychotherapy. As a first-mover in a $25+ billion market, investors may want to take a closer look at the stock.
For more information, visit the company’s website or download their investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
MediPharm is a pioneer in the cannabis industry as it is the first company in Canada to successfully become a Licensed Producer for cannabis oil production without first receiving a cannabis cultivation license.
City Green View is an early-stage cannabis cultivation firm that’s moving through the Health Canada application process.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
